Pemphigus Clinical Trial
Official title:
Comparison of a Personalized Maintenance Therapy Based on the Evolution of Anti-desmoglein Antibodies as Biomarkers of Pemphigus Subclinical Activity, With the Standard Treatment (Rituximab + Corticosteroids) in Pemphigus
Pemphigus diseases are life-threatening chronic autoimmune blistering diseases characterized by split formation within the epidermis and surface-close epithelia accompanied by acantholysis. Autoantibodies (Abs) are mainly directed against two structural proteins of the epidermal/epithelial desmosome, desmoglein (Dsg) 1 and Dsg3. Two main pemphigus variants can be differentiated, pemphigus vulgaris (PV), and pemphigus foliaceus (PF). Diagnosis of PV and PF is based on the combination of the clinical picture, histological picture of acantholysis, direct immunofluorescence microscopy (DIF) of a perilesional biopsy and serology. The present "Ritux 4" trial is the fourth academic study with the French study group on auto immune bullous skin diseases (Groupe Bulle) to assess the use of rituximab in auto immune bullous skin diseases, in particular pemphigus. The 3 previous trials have been published in outstanding Journals (N Engl J Med 2007, Science Transl Med 2013, The Lancet 2017 and 2020), and have led to the approval of rituximab in pemphigus by the FDA in 2018 and EMA in 2019. In addition, an industry-sponsored trial testing rituximab versus mycophenolate mofetil in pemphigus, that the investigators have largely contributed to design has been very recently accepted for publication in the N Engl J Med (2021). The investigator hypothesize that a maintenance therapy using an infusion of 1g of rituximab at Month 6 in patients whose anti-Dsg Abs have not sufficiently decreased at Month 3 after the initial cycle of rituximab (persistence of anti-Dsg1 Abs> 20 UI/ml and/or anti-Dsg3 Abs> 130 UI/ml), and or had an initial PDAI score >45 ( first year of follow-up), and the re-treatment with 1g of rituximab of patients whose anti Dsg Abs re-increase during the evolution of pemphigus after the initial cycle of rituximab (anti-Dsg1 Abs> 20 IU/ml, anti-Dsg3 Abs> 50 UI/ml), could be effective in preventing the occurrence of relapses, thus avoiding to restart a CS treatment, and would provide benefit as compared with the current treatment strategy of retreating patients with 2 g of rituximab (1g at Day0 and Day14) combined with oral CS patients, once a clinical relapse occurs.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05534776 -
Validation of 5-Point Investigator Global Assessments for Pemphigus
|
||
Terminated |
NCT00278642 -
Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders
|
Phase 1 | |
Terminated |
NCT01559155 -
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
|
||
Active, not recruiting |
NCT01974518 -
Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
|
Phase 3 | |
Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
Completed |
NCT00283712 -
Use of Infliximab for the Treatment of Pemphigus Vulgaris
|
Phase 2 | |
Not yet recruiting |
NCT06285435 -
Coagulation Activation in Patients With Pemphigus
|
||
Not yet recruiting |
NCT06454357 -
A Clinical Study of B007 in the Treatment of Pemphigus.
|
Phase 2/Phase 3 | |
Completed |
NCT01299857 -
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
|
Phase 3 | |
Completed |
NCT00960713 -
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
|
N/A | |
Completed |
NCT00213512 -
Effect of Anti CD20 in Pemphigus Desease
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04400994 -
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
|
Phase 2 | |
Recruiting |
NCT02237313 -
Identification of Vulnerability Factors in the Course of Pemphigus Patients
|
N/A | |
Terminated |
NCT03075904 -
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
|
Phase 1/Phase 2 | |
Terminated |
NCT03762265 -
A Study of PRN1008 in Patients With Pemphigus
|
Phase 3 | |
Recruiting |
NCT02365675 -
Wound Dressings for Pemphigus and Pemphigoid
|
N/A | |
Recruiting |
NCT01338103 -
Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
|
N/A | |
Active, not recruiting |
NCT00656656 -
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
|
Phase 2 | |
Completed |
NCT00127764 -
European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus
|
Phase 2/Phase 3 |